GPC2-Specific CAR-T Cells for Neuroblastoma Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, such as CAR-T cell therapy, face challenges in minimizing off-target cell killing and maximizing tumor specificity, particularly for cancers like neuroblastoma, where existing treatments like monoclonal antibodies targeting GD2 result in significant toxicities and limited tumor specificity.
Innovation Solution
Development of a chimeric antigen receptor (CAR) comprising a single-chain antibody variable region fragment (scFv) specific to Glypican 2 (GPC2), with a transmembrane and signal transduction domain, engineered into T cells to selectively target GPC2-positive cancer cells, potentially reducing off-target effects and enhancing anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies targeting GD2 are used to treat neuroblastoma, then anti-tumor activity is improved, but off-target cell killing and toxicities increase
Solution Approach 1:
The patent applies local quality by creating CAR-T cells with highly specific GPC2 binding domains that selectively recognize and bind to GPC2-expressing neuroblastoma cells. This localized specificity ensures that the therapeutic effect is concentrated on the target tumor cells while minimizing off-target effects on healthy tissues, thereby resolving the contradiction between anti-tumor activity and off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by modifying the binding specificity and affinity parameters of the CAR-T cells through engineered scFv domains with optimized sequences (SEQ ID NOS: 5-10). These parameter optimizations enhance the discrimination between GPC2-positive tumor cells and GPC2-negative healthy cells, improving therapeutic efficacy while reducing off-target cell killing.
2Reliability
If existing therapies are used to treat high-risk neuroblastoma, then some tumor control is achieved, but tumor specificity is limited
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic approach into multiple precisely engineered components: specific scFv binding domains (SEQ ID NOS: 5-10), optimized transmembrane domains, and tailored signaling domains. This segmented design allows each component to be optimized independently for its specific function, resulting in CAR-T cells with enhanced tumor specificity and controlled activity.
Solution Approach 2:
The patent uses the GPC2-binding scFv domains as intermediaries that specifically recognize and bind to GPC2 on the surface of neuroblastoma cells. This intermediary binding mechanism provides a bridge between the CAR-T cells and the target tumor cells, enabling precise tumor recognition and selective killing while sparing healthy tissues.
3Power
If CAR-T cells are engineered to recognize target antigens, then anti-tumor activity is enhanced, but off-target effects increase
Solution Approach 1:
The patent replaces the non-specific mechanical killing mechanism of conventional therapies with a highly specific molecular recognition system. The engineered CAR-T cells use programmed scFv domains (SEQ ID NOS: 5-10) that specifically recognize GPC2 epitopes on tumor cells, substituting random or broad-spectrum cell killing with targeted, antigen-specific destruction. This substitution enhances anti-tumor power while minimizing off-target effects.
Solution Approach 2:
The patent enables self-service by engineering CAR-T cells with autonomous GPC2 recognition capabilities. The cells self-direct to GPC2-expressing tumor cells through the specific binding of their CAR receptors, self-activate upon antigen engagement, and self-regulate their cytotoxic activity based on target presence. This self-directed mechanism enhances anti-tumor power while inherently limiting off-target effects through antigen-dependent activation.
Data Source
AI summary
The present disclosure is directed to chimeric antigen receptors binding to Glypican 2, nucleic acids encoding the same, and cells expressing the same, and methods of using such cells to treat cancers that express or overexpress the Glypican 2 antigen.